Biotech | August 02, 2021
Windlas Biotech opens for subscription this week
Proceeds from the IPO will be used for the expansion of the Dehradun facility.
Proceeds from the IPO will be used for the expansion of the Dehradun facility.
The company is confident of commencing production at both Mahad and Chiplun units soon
Growing R&D budgets of global pharmaceutical companies is the opportunity that Veeda and Bioneeds expect to capitalise on.
The company has predominantly built a portfolio into veterinary products
Bayer Zydus Pharma will continue to operate in core therapies with new products in the pipeline
Revenues from operations for FY21 stood at Rs. 202.38 crore as compared to 167.27 crore, up by 21%
Nanoform and Celanese intend to work on formulation development, leveraging each organization's unique formulation expertise.
Dr. Reddy's has the rights to distribute 250mn doses in India
The company is working closely with its six manufacturing partners in India
The Department of Pharma has allocated this drug amongst the states/UTs based on expected supply that will be available from May 10 to May 31, 2021
Subscribe To Our Newsletter & Stay Updated
